Tyrosine Kinase Inhibitor. June-Won Cheong
|
|
- Clement Booker
- 6 years ago
- Views:
Transcription
1 Tyrosine Kinase Inhibitor June-Won Cheong Yonsei University College of Medicine
2 Part I Protein Kinases
3 Cellular communication Signal transduction pathways 3 stages of cell signalling reception transduction response G-protein -linked receptor Protein Kinase receptor
4 Protein Kinases Tyrosine Kinases Serine/threonine Kinases ABL Abelson PKC Protein kinase C KITR c-kit receptor CDK Cyclin-dep. kinase PDGFR PLT-derived-GF receptor MKK1 Mitogen-act. PK kinase 1 EGFR Epidermal-GF receptor RAF Rapidly accelerated fibrosarcoma ERB2R Erb2 receptor CHK1 Checkpoint kinase 1 VEGFR Vascular-endothelial GF receptor mtor Mammalian Target of rapamycin FGFR Fibroblast-GF receptor ROCK RHO-dep. PK NGFR Nerve-GF receptor p38/sapk2a P38/Stress-act. PK2a MLK Mixed-lineage PK
5 Protein Kinases as a Target PKs in a cell Upstream/downstream of relevant oncogenes or tumor suppressor genes Commonality & diversity among ATP-binding sites of PKs Possibility of a step-wise concept validation at the biochemical, cellular & intact animal level as proof of concept in the clinic
6 Protein Kinases & Cancer Overexpression of GFRs EGFR,HER2,HER3,HER4 HER3 HER4 in breast, ovary, lung, H&N and glioblastoma FGFR in lung, ovary and breast PDGFR in glioblastoma IGF-1R in solid tumors Overexpression of GFs TGF-α in carcinoma overexpressing the EGFR PDGF-BB expression in glioblastoma VEGF expression for neo-vascularization (angiogenesis g and metastasis) Altered PK levels and/or activities Bcr-Abl in CML (95%), ALL (15%) c-met in renal carcinoma c-kit in gastric cancers (GIST) Cancers with Onc Ras have deregulated PKC, Raf-kinase (bladder, colon, lung, breast) Deregulation of cell cycle by CdKs
7 Protein Kinase
8 Protein Kinase Inhibitor; PKI Isoquinoline sulfonamides From 1 st PKI (Naphthalene sulfonamide) camp- & cgmp-dept. PKI Hidaka H et al. Biochemistry 1984;23:5036
9 Protein Kinase Inhibitor; PKI Staurosporine Antifungal agent (1977) From Streptomyces Indolocarbazole product Nanomolar inhibitor of PKC K252, CEP-1347, UCN-01, PKC412, etc Tamaoki T et al. Biochem Biophys Res Commun 1986;135:397 Kase H et al. J Antibiot 1986;39:1059
10 Protein Kinase Inhibitor; PKI Knighton DR et al. Science 1991;253:407/414
11 Part II Tyrosine Kinases TKI &
12 Tyrosine Kinases
13
14 Important discoveries in TK Hunter T. Curr Opin Cell Biol 2009;21:140
15 TKI discovery Target TK Inhibitor Company *Bcr-Abl, c-kit, PDGFR STI 571 (Imatinib, GLIVEC) Novartis *, CSF-1R, EPHA4R AMN107 (Nilotinib, ib TASIGNA) Novartis *, SRC, EPHR BMS (Dasatinib, SPRYCEL) BMS *, SRC SKI 606 (Bosutinib) Wyeth-Ayerst EGFR ZD1839 (Gefitinib, IRRESA) AstraZeneca EGFR OSI 774(Erlotinib,TARCEVA) OSI Pharmaceuticals EGFR, ERB2R PKI 166 Novartis EGFR, ERB2R CI 1033 (Canertinib) Pfizer EGFR, ERB2R EKB 569 Wyeth-Ayerst EGFR, ERB2R GW (Lapatinib, TYKERB) GlaxoSmithKline VEGFR PTK 787 Novartis VEGFR ZK Schering-Plough VEGFR SU 5416 (TSU-16) Sugen/Pharmacia Upjohn VEGFR, EGFR ZD 6474 (Vandetanib, ZACTIMA) AstraZeneca VEGFR, FGFR, PDGFR SU 11248(Sorafenib, SUTENT) Pfizer VEGFR, FGFR, PDGFR SU 6668 (TSU-68) Pharmacia Corp. bfgfr PD Pfizer NGFR CEP 2583 Cephalon
16 Tyrosine Kinase Inhibitor; TKI Investigation of catalytic mechanism of EGFR Structure-based searching & discovery of a potent inhibitor Crystallization ti process PD EGFR inhibitor Ward WH et al. Biochem Pharmacol 1994;48:659 Fry DW et al. Science 1994;265:1093 AG1478 EGF-dept. activation of Src-family TK inhibitor Osherov N et al. Eur J Biochem 1994;225:1047
17 Tyrosine Kinase Inhibitor; TKI 4-(Phenylamino)pyrrolopyrimidines By pharmacophore model of ATP binding site EGFR TKI Traxler P et al. J Med Chem 1996;39:2285 PKI166 By optiminization process EGFR/erbB-2 TKI Traxler P et al. Clin Cancer Res 1999;5:3750s
18 Tyrosine Kinase Inhibitor; TKI Folia Pharmacol Jpn. 2003;122:482
19 Part III Individual TKIs
20 Imatinib, Glivec Standard Frontline Tx for CML ; IRIS study Imatinib R A N n = 553 D O M I Z + E IFN-α Ara-C n = 553 Crossover for: Crossover Lack of response Loss of response Intolerance of treatment Reluctance to continue IFN O Brien SG et al. N Engl J Med 2003;348:994
21 Imatinib, Glivec Standard Frontline Tx for CML ; IRIS study O Brien SG et al. N Engl J Med 2003;348:994
22 Imatinib, Glivec Standard Frontline Tx for CML ; IRIS study MCyR PFS O Brien SG et al. N Engl J Med 2003;348:994
23 Imatinib, Glivec Standard Frontline Tx for CML ; IRIS study 7 yrs after All randomized to imatinib (n= 553; 100%) Still receiving study imatinib (n = 332; 60%) Discontinued study imatinib* (n = 221; 40%) In CCR (n = 317; 57%) No CCR (n = 15; 3%) Safety (n = 43; 8%) Efficacy (n = 82; 15%) Other (n = 96; 17%) Alive Dead Alive Dead Alive Dead (n = 17; (n = 26; (n = 52; (n = 30; (n = 81; (n = 15; 40%) 60%) 63%) 37%) 84%) 16%) O Brien SG et al. Blood 2008;112: Abstract 186.
24 Imatinib, Glivec Standard Frontline Tx for CML ; IRIS study 7 yrs after ut Event % Witho Survival: deaths associated with CML Overall Survival Estimated OS at 7 years is 86% (94% considering only CML-related deaths) O Brien SG et al. Blood 2008;112: Abstract year after random.
25 Imatinib, Glivec Standard Frontline Tx for CML ; IRIS study 7 yrs after 100 % of Available Samples BCR-ABL% (IS) 0.1% 0.01% Sample Analysis Time Points (months) Hughes et al. Blood 2008;112: Abstract 334.
26 Imatinib, Glivec Standard Frontline Tx for CML ; Failure / Suboptimal Response Time Failure Suboptimal Response Warnings Dx 3 m No HR < CHR 6 m No CHR or CyR < PCyR High risk Del9q+ Additional ch somal abnls in Ph+ cells 12 m < PCyR PCyR < < CCyR Any MR < MMR 18 m < CCyR < MMR Any time Loss of CHR Loss of CCyR Mutation with high insensitivity to Glivec Additional ch somal abnls in Ph+ cells Loss of MMR Mutation with low insensitivity to Glivec Increase in BCR- ABL level Other ch somal abnls in Ph-cells Baccarani M et al. Blood 2006;108:1809.
27 Imatinib, Glivec Standard Frontline Tx for CML ; Failure / Suboptimal Response % CCyR >6 months s(n=81) ( ) Suboptimal 60 (n=19) (n=16) 30 Failure (n=16) Months since randomization CyR at 6 months (Ph+) 1-35% 66-95% 36-65% >95% Druker et al. Blood 2003; 102: Abstract 634
28 Imatinib, Glivec Standard Frontline Tx for CML ; Failure / Suboptimal Response % Wit thout Ev vent BCR-ABL % (IS) at 18 months 0.1% (n = 164) >0.1-1% (n = 47) 20 >1-10% (n = 25) 10 >10% (n = 13) % P = % 62% 58% Hughes et al. Blood 2008;112: Abstract 334.
29 Imatinib, Glivec Standard Frontline Tx for CML ; Failure / Suboptimal Response Standard Frontline Tx for CML ; AP and BC patients Overall CyR 48% Overall CyR 17% PFS Palandri F et al. Haematologica 2009;94:205 Palandri F et al. Haematologica 2008;93:1792
30 Imatinib, Glivec Standard Frontline Tx for CML ; Failure / Suboptimal Response Standard Frontline Tx for CML ; AP and BC patients Standard Frontline Tx for CML ; Bcr/Abl mutations 20% Data from the GIMEMA CML WP on 655 imatinib-resistant patients 15% 10% 5% Catalytic Activation P-loop domain loop L248V G250E Q252R/H V289A M343T D276G E281A/K M351T T277A E279K E255K/V E292V T315I Y253F/H F311L/I F317L F359V/I E355G/D H396R/P L364I L387M/F L384M F382L S417Y/F V379I E453G/K E459K/Q A380T F486S
31 Imatinib, Glivec Standard Frontline Tx for CML ; Failure / Suboptimal Response Standard Frontline Tx for CML ; AP and BC patients Standard Frontline Tx for CML ; Bcr/Abl mutations. 2 nd generation TKIs Nilotinib Dasatinib Bosutinib
32 Imatinib Nilotinib Dasatinib Bosutinib
33 Potency & Selectivity of TKIs Imatinib: PDGFR > Kit > BcrAbl > Src (Phos IC 50 ) 72 nm 99 nm 192 nm >1000 nm Dasatinib: Src > BcrAbl > PDGFR > Kit (Phos IC 50 ) 0.1 nm 1.8 nm 2.9 nm 18 nm Nilotinib: BcrAbl > PDGFR > Kit > Src (Phos IC 50 ) 19 nm 75 nm 209 nm >1000 nm Mestan J et al. Blood. 2004;104: Abstract Weisberg E et al. Cancer Cell 2005;7:129.
34 Nilotinib, as a Second Tx for CP pts % Patients, % % 59% 56% 65% 44% 41% 51% n Overall No BL CHR Overall Imatinib- Resistant Imatinib- Intolerant Overall Imatinib- Resistant 95 Imatinib- Intolerant CHR MCyR CCyR Patients with a minimum follow-up of 24 months Kantarjian HM, et al. J Clin Oncol. 2009;27(15S): Abstract 7029.
35 Nilotinib, as a Second Tx for CP pts 100 PFS 89% 84% 78% % Without Prog gression or Death Number of patients = 189 Number failed = 35 = Censored observations Months Since MCyR Kantarjian HM, et al. Blood. 2008;112: Abstract 3238.
36 % Alive Nilotinib, as a Second Tx for CP pts OS 95% 87% Number of patients = 321 Number failed = 44 = censored observations Months Since Start of Treatment 87% of patients were estimated to be alive on nilotinib at 24 months Kantarjian HM, et al. J Clin Oncol. 2009;27(15S): Abstract 7029.
37 Dasatinib, as a Second Tx for CP pts For imatinib-resistant or intolerant CML-CP pts. Prior imatinib mg (48%), 600 mg (52%) Non-Hema SE(G3,4): 3% Hema SE(G3,4): 22-49% MCyR PFS Hochhaus A et al. Blood 2007;109:2303
38 Dasatinib, as a Second Tx for CP pts CHR MCyR CCyR % mg 70 mg 140 mg 50 mg Once Daily BID Once Daily BID Shah NP, et al. Blood. 2008;112: Abstract 3225.
39 Dasatinib, as a Second Tx for CP pts % % With hout Loss s of MCyR month response rates MCyR CCyR 62% 53% Months since MCyR 369 of 387 patients evaluable for molecular response Shah NP, et al. Blood. 2008;112: Abstract 3225.
40 Dasatinib, as a Second Tx for CP pts % 94% OS % 80% PFS % Months Shah NP, et al. Blood. 2008;112: Abstract 3225.
41 Nilotinib/Dasatinib, AEs Dasatinib 70 mg BID, Nilotinib 400 mg BID Dasatinib Nilotinib Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Myelotoxicity (Thrombocytopenia & Neutropenia) Pleural Effusion (Peripheral Edema) 26 (29) 9 (1) 1 (6) 1 (0) Bleeding Hyperglycemia Lipase elevation Stone RM, et al. Blood. 2007;110: Abstract 734 / Kantarjian HM, et al. Blood. 2007;110: Abstract 735.
42 Nilotinib/Dasatinib, CP as a Second Tx for 2yr% Nilotinib Dasatinib CHR MCyR CCyR DMCyR D.MCyR PFS 80 OS 87 94
43 Nilotinib/Dasatinib, AP as a Second Tx for 2yr% Nilotinib Dasatinib CHR MCyR CCyR DMC D.MCyR 66 (after MCyR) 75 (after MCyR) PFS 55 OS 66 le Coutre PD, et al. J Clin Oncol. 2009;27(15S): Abstract 7057 / Kantarjian HM, et al. Blood. 15 April Epub ahead of print.
44 Dasatinib, as a Second Tx for BC pts 116 imatinib-resistant or intolerant CML-BC pts. Non-Hema SE(G3,4): 0-24% Hema SE(G3,4): 12-14% MHR PFS Cortes J et al. Blood 2007;109:3207
45 Dasatinib for nilotinib-resistant Pts For imatinib & nilotinib-resistant Ph(+) leukemia N= 13 (CP 1, AP 9, BC 3) Bcr-Abl mutation 100% 140 mg/d (twice daily) Median Tx duration: 4 months (1-10) OR: 57% CHR: 43% CyR: 30% Quintas-Cardama A et al. Blood 2006;109:497
46 Nilotinib for Dasatinib-resistant Pts % % % CHR MCyR CCyR Giles F et al. Blood 2008;112:1110
47 Mutations recovered after TKI therapy * * Imatinib Dasatinib Nilotinib * * % 10 * * 5 0 * * * G250E Y253F/H E255G/K V299L F311I/L T315I F317L/V M351T E355G/A F359C/V H396P/R BCR/ABL Mutation * T315I & F359V recovered after treatment with bosutinib * Jabbour E, et al. Blood. 2006;108: Abstract 750.
48 2 nd generation TKIs Randomized Trials for Frontline Tx Study Imatinib 2 nd TKI No. of Pts Year started USA-SWOG 400/800 Dasatinib Novartis 400 Nilotinib Wyeth 400 Bosutinib 2007
49 Nilotinib, as a frontline Tx 50% 80% 90% 83% 98% 97% CCyR 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% High Risk (n=10) Non-High Risk (n=63) < CCyR Months Rosti G, et al, Presented at: 14 th Congress of the EHA; 2009: Berlin, Germany. Abstract 1090.
50 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Nilotinib, as a frontline Tx 3% 21% 52% 66% 73% 85% MMR < MMR NE Months Rosti G, et al, Presented at: 14 th Congress of the EHA; 2009: Berlin, Germany. Abstract 1090.
51 Dasatinib, as a frontline Tx Respon nse N = 48 N = 43 N = 37 N = 32 N = 25 N = CCyR PCyR Pe ercenta ge with Months on Therapy Cortes J, et al. Blood. 2008;112: Abstract 446.
52 Dasatinib, as a frontline Tx e with Re esponse Pe ercentag % MMR % CMR Months N Cortes et al. Blood 2008;112: Abstract 182.
53 Nilotinib/Dasatinib, CP as a Frontline Tx for 1yr% Nilotinib Dasatinib CCyR* MMR * Imatinib: 74% 2 nd generation TKIs can improve outcome of pts with early CP-CML Responses with nilotinib/dasatinib are better & faster than imatinib Nilotinib is better tolerated and more selective than dasatinib
54 More approved TKIs. Bcr-Abl ATP-Binding Abl & Src T315I-Active Nonkinase Inhibition Imatinib Dasatinib MK AAG Nilotinib Bosutinib KW-2449 HDAC INNO-406 XL228 DAC AT9283 HHT PHA
55 CASE 1 68/F, CML-CP in Jan Frontline Tx: Imatinib 400 mg/d. At 12 months of Tx: CCyR After 2 month, WBC 25,000/ul & 15 % basophils, BM: Blast 16%. What step would you take next? Continue imatinib at 400 mg/day Increase the dose of imatinib to 800 mg/day Switch therapy to a 2 nd generation TKI Recommend immediate allohsct
56 Imatinib, Glivec Standard Frontline Tx for CML ; Failure / Suboptimal Response Time Failure Suboptimal Response Warnings Dx 3 m No HR < CHR 6 m No CHR or CyR < PCyR High risk Del9q+ Additional ch somal abnls in Ph+ cells 12 m < PCyR PCyR < < CCyR Any MR < MMR 18 m < CCyR < MMR Any time Loss of CHR Loss of CCyR Mutation with high insensitivity to Glivec Additional ch somal abnls in Ph+ cells Loss of MMR Mutation with low insensitivity to Glivec Increase in BCR- ABL level Other ch somal abnls in Ph-cells Baccarani M et al. Blood 2006;108:1809.
57 CASE 1 68/F, CML-CP in Jan Frontline Tx: Imatinib 400 mg/d. At 12 months of Tx: CCyR After 2 month, WBC 25,000/ul & 15 % basophils, BM: Blast 16%. What step would you take next? X Continue imatinib at 400 mg/day Y Increase the dose of imatinib to 800 mg/day Z Switch therapy to a 2nd generation TKI [ Recommend immediate allohsct Pt shows imatinib failure after optimal response Y than Z
58 CASE 2 44/F, CML-CP, with sibling HLA matched donor Frontline Tx: Imatinib 400 mg/d. Grade 2 fluid retentions Ph(+) metaphases in BM: 30% at 6 months 50% at 12 months Imatinib plasma level: adequate & No mutations What step would you take next? Increase the dose of imatinib to 800 mg/day Switch therapy to nilotinib 400 mg twice daily Switch therapy to dasatinib 100 mg daily Recommend immediate allohsct
59 CASE 2 44/F, CML-CP, with sibling HLA matched donor Frontline Tx: Imatinib 400 mg/d. Grade 2 fluid retentions Ph(+) metaphases in BM: 30% at 6 months 50% at 12 months Imatinib plasma level: adequate & No mutations What step would you take next? X Increase the dose of imatinib to 800 mg/day Y Switch therapy to nilotinib 400 mg twice daily Z Switch therapy to dasatinib 100 mg daily [ Recommend immediate allohsct Pt shows imatinib failure after optimal response Y than Z or X
60 Thanks
IRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationJuan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationIS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London
IS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London Tell me generals, are we politicians necessary? I have to admit defeat before starting
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationDose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationNEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationSuboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
REVIEW IMATINIB TREATMENT FOR CHRONIC MYELOID LEUKEMIA Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? ELIAS JABBOUR, MD; JORGE E. CORTES,
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationCML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008
Novità dall EHA >> [ Leucemia mieloide cronica ] CML EHA: what s new? Relatore: G. MARTINELLI 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia mieloide cronica - Copyright FSE 1 CML EHA:
More informationCML Treatment Failure: More Threatening Than It Appears. Mutation Testing
CML Treatment Failure: More Threatening Than It Appears Mutation Testing Content Mutations and treatment failure Single mutations Compound mutations Mutation testing Guideline recommendations Summary 2
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationTyrosine kinase inhibitors (TKIs) act by preventing disease
SUBJECT REVIEW Emergence of BCR-ABL Kinase Domain Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors Iulia D. Ursan, PharmD; Ruixuan
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationDecision Making in CML 2010
Decision Making in CML 2010 Imatinib is the standard treatment for chronic myeloid leukaemia (CML), but approximately 25% of patients are resistant or non-responsive to imatinib. 1 While physicians have
More informationThe speaker has no financial relationships with a commercial interest to disclose and no conflicts of interest to resolve.
Hana Safah MD Professor of Medicine Tulane University School of Medicine Director of the SCT program, Tulane Medical Center The speaker has no financial relationships with a commercial interest to disclose
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationImplementation of Management Guidelines
Implementation of Management Guidelines For Chronic Myeloid Leukemia Perspectives in the United States David Rizzieri, MD; and Joseph O. Moore, MD ABSTRACT Clinical practice guidelines are developed to
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationEvaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada
Evaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada Jeffrey H. Lipton, Sergio Iannazzo, Silvia Chiroli, Lisa McGarry 06 CADTH
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationSecond-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Critical Reviews in Oncology/Hematology 82 (2012) 159 170 Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase Gianantonio Rosti, Fausto Castagnetti,
More informationMeasuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia
Review Article Measuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia Jerald P. Radich, MD In patients with chronic myeloid leukemia (CML), the hallmark Philadelphia chromosome is the marker
More informationWhat is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas
What is New in CML 2018 Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas Final Results CML-IV Molecular Response with Imatinib 1538 pts newly
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More informationLong-term side effects, comorbidities & their impact on choice of treatment CML management and quality of life. Andreas Hochhaus
Long-term side effects, comorbidities & their impact on choice of treatment CML management and quality of life Andreas Hochhaus Frankfurt I 27.5.2017 sola dosis facit venenum Paracelsus 1493-1541 Swiss
More informationExtending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
Oncol Rev (2009) 3:59 70 DOI 10.1007/s12156-009-0004-9 REVIEW Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors Michael G.
More informationNEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
More informationt(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case
CHRONIC MYELOID LEUKAEMIA Diagnostic Criteria Chronic phase CML t(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case Maximally cellular marrow
More informationChronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018
Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018 Disclosures Richard A. Larson, MD Research funding to the University of Chicago: Astellas Celgene Daiichi
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More information35 Current Trends in the
35 Current Trends in the Management of Chronic Myelogenous Leukemia Abstract: CML is a hematopoietic stem cell disease which is characterized by the presence of Philadelphia chromosome (Ph-chromosome)
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationThe development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
J Cancer Res Clin Oncol (2013) 139:1971 1984 DOI 10.1007/s00432-013-1488-z REVIEW The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in
More informationKwan, TK; Ma, ESK; Chan, YY; Wan, TSK; Liu, HSY; Sim, JPY; Yeung, YM; Lie, AKW; Yip, SF
Title Author(s) BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib fail Kwan, TK; Ma, ESK;
More informationCML Clinical Case Scenario
CML Clinical Case Scenario Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive Cancer Center at
More informationShould nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)?
Should nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)? http://test.metromomsblog.org/wp-content/uploads/2010/02/tortoise-and-the-hare.jpg D. Van
More informationULTRA-DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN FOR BETTER THERAPEUTIC TAILORING OF PHILADELPHIA CHROMOSOME-POSITIVE LEUKEMIA PATIENTS
ULTRA-DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN FOR BETTER THERAPEUTIC TAILORING OF PHILADELPHIA CHROMOSOME-POSITIVE LEUKEMIA PATIENTS Simona Soverini, PhD Department of Experimental, Diagnostic and
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Nilotinib (Tasigna ) for the 1 st -line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase DSD: Horizon Scanning in Oncology Nr. 15
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationThe Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon
The Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon Imatinib revolutionized the treatment of chronic myelogenous leukemia (CML), improving the prognosis to such an extent that the
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More informationCURRENT MOLECULAR DIAGNOSTICS IN HEMATOONCOLOGY
Third Slovenian congress of hematology and transfusion medicne, Podcetrtek, April 08 Third Slovenian congress of hematology and transfusion medicne, Podcetrtek, April 08 CURRENT MOLECULAR DIAGNOSTICS IN
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 March 2007 SPRYCEL 20 mg, film-coated tablet, blister (377 637-9) SPRYCEL 20 mg, film-coated tablet, bottle (377
More informationCHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It
CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It Jeffrey H Lipton PhD MD Princess Margaret Cancer Centre Professor of Medicine University of Toronto CAGPO Annual Conference St. John
More informationAn update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
Singapore Med J 2012; 53(1) : 57 An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia Bee PC 1, MD, MMed, Gan GG 1, MBBS, FRCP, Tai YT 1, MBBS,
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationAdecade ago imatinib mesylate, the first tyrosine
CHRONIC MYELOID LEUKEMIA: AFTER A DECADE OF IMATIINIB Monitoring disease response to tyrosine kinase inhibitor therapy in CML Timothy P. Hughes 1 and Susan Branford 1 1 Centre for Cancer Biology, Departments
More informationCell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger
Cell, Volume 141 Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Figure S1. RTK Mutations in Diseases Locations of gain-of-function (green arrows)
More informationStopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
More informationDiagnosis and Management of Chronic Myeloid Leukaemia
Diagnosis and Management of Chronic Myeloid Leukaemia Dr Simon Watt Dr Katherine O Neill Dr Fiona Dignan Written July 2017 Prof Tim Somervaille Review July 2019 1 Table of Contents 1.0 Introduction 3 2.0
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationTaiwan Guidelines for the Management of Chronic Myeloid Leukemia
Taiwan Guidelines for the Management of Chronic Myeloid Leukemia Taiwan CML Study Group Coordinator: Lee-Yung Shih 2013/11/30 1 Contents Initial work-up at diagnosis and define baseline prognostic factors
More informationTalpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:
References Sprycel Talpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:2531-2541. National Comprehensive Cancer Network. Clinical Practice
More information